摘要
目的：探讨多西紫杉醇联合顺铂治疗晚期非小细胞肺癌（Non-Small Cell Lung Cancer,NSCLC）的临床疗效和不良反应。方法：42例晚期NSCLC患者,采用多西紫杉醇75 mg/m^2加入5%葡萄糖注射液500 mL中静脉滴注1 h,第1天;顺铂25 mg/m^2加入0.9%氯化钠注射液500 mL中静脉滴注,第1-3天。21 d为一个周期,至少二个周期评价疗效。结果：42例患者中,完全缓解（CR）2例,部分缓解（PR）19例,无变化（NC）13例,进展（PD）8例;初治组有效率为54.5%,复治组有效率为45.0%,两组比较,差异无统计学意义（P〉0.05）。中位生存期为10.9个月,中位疾病进展时间为4.8个月,1年生存率为40.5%。Ⅲ-Ⅳ度不良反应：白细胞减少为33.3%,脱发为19.0%,口腔黏膜炎为11.9%。结论：多西紫杉醇联合顺铂治疗晚期非小细胞肺癌有较好的疗效,不良反应轻,耐受性好,值得进一步研究。
Objective：To compare the efficacy and safety of docetaxel plus cisplatin in the treatments of patients with advanced non-small cell lung cancer. Methods：Forty-two patients with advanced NSCLC diagnosed pathologically were enrolled into the investigation with age from 28 to 73 years and a ECOG PS of 0-2. The patients received docetaxel 75 mg/m^2 on day 1 ,and cisplatin 25 mg/m^2 on day 1-3. The chemotherapy was repeated every 21 days. All the patients received at least 2 cycles. Results： Objective response was obtained in 50.0% （21/42） of patients（2 complete and 19 partial response） ,whereas 13 patients had no change and 8 patients were progressive. Significant difference not existed between the naive patients and retreated patients（54. 5 5 vs 45.0 ,P〉0.05）. Median times to tumor progression was 4.9 months. The median survival times was 10.9 months and 1：year survival rate reached 40.5 %. The main toxicities included myelosuppression, nausea, vomiting and alopecia. Conclusion： Docetaxel combined with cisplatin is effective in the treatment of advanced NSCLC ,with mild to moderate side effects.
出处
《实用临床医学（江西）》
CAS
2007年第6期37-38,42,共3页
Practical Clinical Medicine
关键词
非小细胞肺癌
多西紫杉醇
顺铂
化疗
non-small cell lung cancer
docetaxel
cisplatin
chemiotherapy
